Vaccination with allogeneic dendritic cells fused to carcinoma cells induces antitumor immunity in MUC1 transgenic mice

Clinical Immunology

Volumn 101, Issue 2, 2001, Pages 192-200

  Tanaka, Yasuhiro ^a   Koido, Shigeo ^a   Chen, Dongshu ^a   Gendler, Sandra J ^b   Kufe, Donald ^a   Gong, Jianlin ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Allogeneic and syngeneic DC fusions; Anti tumor immunity; Fusion cell vaccines; Reversal of tolerance to MUC1

Indexed keywords

CANCER VACCINE; CHROMIUM 51; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; TUMOR ANTIGEN;

ANIMAL CELL; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; CARCINOMA CELL; DENDRITIC CELL; FEMALE; FLOW CYTOMETRY; IMMUNE RESPONSE; IMMUNIZATION; LUNG METASTASIS; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE; TUMOR IMMUNITY; VACCINATION;

EID: 0035181956     PISSN: 15216616     EISSN: None     Source Type: Journal    
DOI: 10.1006/clim.2001.5112     Document Type: Article

References (40)

1. Signals arising from antigen presenting cells
2. Dendritic cells pulsed with protein antigens in vitro can prime antigen-specific, MHC-restricted T cells in situ
3. Antigen acquisition by dendritic cells: Intestinal dendritic cells acquire antigen administered orally and can prime naive T cells in vivo
4. Primary stimulation by dendritic cells induces antiviral proliferative and cytotoxic T cell responses in vitro
5. Generation of antigen-specific CD8+ CTLs from naive precursors
6. Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes
7. Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity
8. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity
9. Generation of antimelanoma cytotoxic T lymphocytes from healthy donors after presentation of melanoma-associated antigen-derived epitopes by dendritic cells in vitro
10. Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo
11. Induction of antigen-specific antitumor immunity with adenovirus-transduced dendritic cells
12. Dendritic cells retrovirally transduced with a model antigen gene are therapeutically effective against established pulmonary metastases
13. Antigen presentation in retroviral vector mediated gene transfer in vivo
14. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells
15. Reversal of tolerance to human MUC1 antigen in MUC1 transgenic mice immunized with fusions of dendritic and carcinoma cells
16. Activation of antitumor cytotoxic T lymphocytes by fusions of human dendritic cells and breast carcinoma cells
17. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids
18. Induction of primary human CD8+ T lymphocyte responses in vitro using dendritic cells
19. Class II MHC/peptide complexes are released from APC and are acquired by T cell responders during specific antigen recognition
20. Generation of primary peptide-specific CD8+ cytotoxic T-lymphocytes in vitro using allogeneic dendritic cells
21. + helper T cells
22. In vitro generation of allospecific human CD8+ T cells of Tc1 and Tc2 phenotype
23. Allogeneic dendritic cell induction of HIV-specific cytotoxic T lymphocyte responses from T cells of HIV type 1-infected and uninfected individuals
24. Dendritic cells prime in vivo alloreactive CD4 T lymphocytes toward type 2 cytokine- and TGF-beta-producing cells in the absence of CD8 T cell activation
25. The molecular basis of allorecognition
26. Conformational differences in major histocompatibility complex-peptide complexes can result in alloreactivity
27. The presentation of self and allogeneic MHC peptides to T lymphocytes
28. The repertoire of T cells shaped by a single MHC/peptide ligand
29. The MHC reactivity of the T cell repertoire prior to positive and negative selection
30. The alloreactive and self-restricted CD4+ T cell response directed against a single MHC class II/peptide combination
31. Tolerance and immunity to MUC1 in a human MUC1 transgenic murine model
32. T cell suppression as a mechanism for tolerance to MUC1 antigen in MUC1 transgenic mice
33. Isolation and sequencing of a cDNA coding for the human DF3 breast carcinoma-associated antigen
34. Therapeutic antitumor response after immunization with an admixture of recombinant vaccinia viruses expressing a modified MUC1 gene and the murine T-cell costimulatory molecule B7
35. Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors
36. In situ tetramer staining of antigen-specific T cells in tissues
37. Selection and characterization of MUC1-specific CD8+ T cells from MUC1 transgenic mice immunized with dendritic-carcinoma fusion cells
38. Dendritic cells fused with mastocytoma cells elicit therapeutic antitumor immunity
39. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines
40. The allogeneic response and tumor immunity